Technical · Educational · Advanced

DIY mRNA Production

A technical overview of what mRNA synthesis looks like in a research-lab or well-resourced DIY setting. What the workflow requires, what can go wrong, and why this is not a casual undertaking.

🔬 This page is educational — describing the workflow as reported in open literature and DIYbio communities. HighPeptides is not a how-to for producing therapeutics.
5
Major Workflow Steps
~$20k
Typical Starter Lab Cost
BSL-1
Minimum Safety Level

How It Works

🧬
IVT Synthesis

In Vitro Transcription: uses T7 RNA polymerase + NTPs + a DNA template. Commercial kits (e.g., NEB HiScribe) produce mg quantities of mRNA in a tube reaction over hours.

🎩
5' Capping

mRNA stability requires a 5' cap. Done via cap analog (ARCA) during IVT, or by post-transcriptional capping with vaccinia capping enzyme. Cap-0 vs Cap-1 matters for immunogenicity.

🧼
Purification

Remove unincorporated NTPs, template DNA, and contaminating dsRNA. Standard: LiCl precipitation, then silica column, then sometimes HPLC. dsRNA is a major immunogenicity driver (hard to fully remove).

💊
LNP Formulation

mRNA alone degrades in blood. Lipid nanoparticles (LNP) protect and deliver. Requires microfluidic mixing, specific ionizable lipids (SM-102, ALC-0315), PEG-lipid, cholesterol, and DSPC. Formulation is where most DIY attempts fail.

What the Data Shows

IVT synthesis difficulty
Kit-based, reproducible
Low
Capping + modified nucleotide integration
Standard protocols exist
Medium
dsRNA removal and purity control
Immunogenicity driver
High
LNP formulation
Microfluidics + lipid chemistry
Hardest

Key Takeaways

What We Know
  • IVT synthesis with commercial kits is the most tractable step
  • Capping, purification, and LNP formulation are where quality breaks down
  • Modified nucleotides (pseudouridine) reduce immunogenicity
  • dsRNA contamination is the #1 driver of inflammation on injection
  • LNP formulation is capital-intensive and hard to DIY correctly
What We Don't Know
  • Small-scale mRNA production has no clinical quality assurance
  • LNP quality varies by orders of magnitude across setups, which affects biodistribution
  • Producing mRNA for human injection is illegal in most jurisdictions
  • BSL-1+ conditions are minimum; contamination compromises everything
  • Open-source literature is educational; real application requires regulated infrastructure

Frequently Asked Questions

Is this legal?

Producing mRNA as a research compound in the US is legal in a research-lab context. Injecting DIY-produced mRNA into humans is not legal — it falls under FDA drug regulation. DIYbio communities have explored this academically.

What's the hardest step?

LNP formulation. IVT synthesis is kit-based and reproducible; capping is solved by modern protocols; purification is work but feasible. LNPs require microfluidic mixing, specific lipid chemistry, and quality control that's hard to replicate in small-lab settings.

Can I do this at home?

Practically — no, not in a way that produces safe injectable product. The capital, expertise, and QC required are substantial. The workflow exists in research labs and specialized contract manufacturers for a reason.

Why does HighPeptides cover this?

mRNA and peptide therapeutics are related technologies — both are biologic modalities with overlapping production principles. Understanding mRNA production helps contextualize how peptide therapeutics are made and why vendor quality varies.

Recommended Products

Support supplements and gear relevant to this protocol.

Affiliate links support HighPeptides at no extra cost.

Disclaimer

This page is educational. It describes the technical workflow of mRNA production as covered in open literature. It is not a how-to for producing therapeutics for human use.

Producing injectable biologics outside of regulated infrastructure is illegal in most jurisdictions and carries real health risks. Not medical or technical advice.

ESC
🔍 Search peptides, guides, and research...
↑↓ navigate   ↵ open   esc close